

U.S.S.N. 09/373,403

Page 6

REMARKS

Formal Matters

Claims 12-18 are canceled and new claims 30-49 are added. New claims 30-49 correspond to original claims 1-11 and 19-27 that were inadvertently canceled when the above-referenced continuation application was filed.

No new matter is added by these amendments.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made".

If the Examiner believes a telephone conference would expedite the prosecution of this application, the Examiner is invited to call the undersigned at the number indicated below

This response is timely submitted with a transmittal letter and applicants authorize the Commissioner to charge our Deposit Account 07-0630 for any fees required or credits due for any extensions of time necessary to maintain the pendency of this application.

Respectfully submitted,
GENENTECH, INC.

Date: May 14, 2001

By:


Deirdre L. Conley, Ph.D.

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

Doc #90593

U.S.S N 09/373,403

Page 7

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Claims:**

Claims 12-18 have been cancelled.

Claims 30-49 have been added

-- 30. A method of preparing a multispecific antibody comprising a first polypeptide and at least one additional polypeptide, wherein

(a) the first polypeptide comprises a multimerization domain forming an interface positioned to interact with an interface of a multimerization domain of the additional polypeptide,

(b) the first and additional polypeptides each comprise a binding domain, the binding domain comprising a heavy chain and a light chain, wherein the variable light chains of the first and additional polypeptides comprise a common sequence, the method comprising the steps of:

(I) culturing a host cell comprising nucleic acid encoding the first polypeptide and additional polypeptide, and the variable light chain, wherein the culturing is such that the nucleic acid is expressed; and

(ii) recovering the multispecific antibody from the host cell culture.

31. The method of claim 30, wherein the nucleic acid encoding the first polypeptide or the nucleic acid encoding the additional polypeptide, or both, has been altered from the original nucleic acid to encode the interface or a portion thereof.

32. The method of claim 31 wherein the multimerization domains of one of the first or additional polypeptides, or both, are altered to comprise a free thiol-containing residue which is positioned to interact with a free thiol-containing residue of the interface of the other of the first or additional polypeptide such that a disulfide bond is formed between the first and additional polypeptides, wherein the nucleic acid encoding the first polypeptide has been altered from the original nucleic acid to encode the free thiol-containing residue or the nucleic acid encoding the additional polypeptide has been altered from the original nucleic acid to encode the

U S S N 09/373,403

Page 8

free thiol-containing residue, or both.

33. The method of claim 30 wherein the multimerization domains of the first and additional polypeptides comprise a protuberance-into-cavity interaction, wherein the method further comprises:

generating a protuberance by altering the original nucleic acid encoding the first polypeptide to encode an import residue having a larger side chain volume than the original residue, and

generating a cavity by altering the original nucleic acid encoding the additional polypeptide to encode an import residue having a smaller side chain volume than the original residue.

34. The method of claim 33, wherein the steps of generating a protuberance or generating a cavity, or both, occurs by phage display selection.

35. The method of claim 33 wherein the import residue having a larger side chain volume than the original residue is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W), isoleucine (I) and leucine (L).

36. The method of claim 33 wherein the import residue having a smaller side chain volume than the original residue is selected from the group consisting of glycine (G), alanine (A), serine (S), threonine (T), and valine (V), and wherein the import residue is not cysteine (C).

37. The method of claim 30 wherein the first and additional polypeptide each comprise an antibody constant domain

38. The method of claims 37 wherein the first and additional polypeptide each comprise an antibody constant domain selected from the group consisting of a C_H3 domain and

U.S.N. 09/373,403

Page 9

an IgG.

39. The method of claim 30 wherein the heteromultimer is a multispecific immunoadhesin.

40. The method of claim 30 wherein step (I) is preceded by a step wherein the nucleic acid encoding the first and additional polypeptide is introduced into the host cell.

41. A host cell comprising nucleic acid encoding the heteromultimer of claim 13.

42. The host cell of claim 41 wherein the host cell is a mammalian cell.

43. A method of preparing a multispecific antibody comprising:

(a) selecting a first nucleic acid encoding a first polypeptide comprising an amino acid residue in the interface of the first polypeptide is replaced with an amino acid residue on an additional polypeptide, and selecting at least one additional nucleic acid encoding at least one additional polypeptide so that the amino acid residue on the additional polypeptide specifically interacts with the amino acid residue on the first polypeptide, thereby generating a stable interaction between the first and additional polypeptides;

(b) selecting a light chain encoding nucleic acid sequence, wherein the light chain is meant to associate with the binding region of each first and additional polypeptide of the multispecific antibody;

(c) introducing into a host cell the first and additional nucleic acids and the light chain-encoding nucleic acid, and culturing the cell so that expression of the first and additional nucleic acids and the light chain-encoding nucleic acid occurs to form the bispecific antibody;

(d) recovering the multispecific antibody from the cell culture.

44. The method of claim 43, wherein at least one of the first and additional nucleic acids

U.S.S.N. 09/373,403

Page 10

of step (a) are altered from the original nucleic acid to encode an amino acid in the interface that interacts with an amino acid of the first or additional amino acid residue thereby generating the stable interaction.

45. The method of claim 44 wherein the altering comprises generating a protuberance-into-cavity interaction at the interface between the first and additional polypeptides.

46. The method of claim 44 wherein the altering comprises importing a free thiol-containing residue into the first or additional polypeptide or both, such that the free thiol-containing residues interact to form a disulfide bond between the first and additional polypeptides.

47. The method of claim 43 wherein the first and additional polypeptide each comprise an antibody constant domain.

48. The method of claim 47 wherein the antibody constant domain is a C_H3 domain.

49. The method of claim 48 wherein the antibody constant domain is from a human IgG.--